Biotechnology
Biopharmaceutical
Pharmaceutical
TG Therapeutics
$7.569876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$7.56
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
-$0.02 (-0.26%) Today
$0.00 (0.00%) As of 4:05 PM EDT after-hours
Why Robinhood?
You can buy or sell TGTX and other stocks, options, ETFs, and crypto commission-free!
About TGTX
TG Therapeutics, Inc. Common Stock, also called TG Therapeutics, is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Read More Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY.
Employees
105
Headquarters
New York, New York
Founded
1993
Market Cap
671.14M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
1.06M
High Today
$7.76
Low Today
$7.48
Open Price
$7.62
Volume
756.66K
52 Week High
$12.90
52 Week Low
$3.32
Collections
Biotechnology
Biopharmaceutical
Pharmaceutical
Health
Therapy
Technology
Price Paid on Robinhood
1% Lower
Right Now
52 Week Low
$3.32
Average Price Paid
$7.63
52 Week High
$12.90
Analyst Ratings
100%
of 7 ratings
Buy
100%
Hold
0%
Sell
0%
TGTX Earnings
-$0.68
-$0.59
-$0.51
-$0.42
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
—
Actual
Expected Aug 7, Pre-Market